This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through March 4, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 25% and 99.96%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Ligand (LGND) Posts Long-Term Outlook, Updates Portfolio Progress
by Zacks Equity Research
Ligand (LGND) aims to generate annual core sales of around $290 million by 2028. It expects revenues from royalties to witness a CAGR of 16% over the next five years.
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
by Zacks Equity Research
Ovid Therapeutics (OVID) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ovid Therapeutics (OVID) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of 14.29% and 17.58%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of -5.56% and 10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Ovid Therapeutics (OVID) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Industry Outlook Highlights: Moderna, Amgen, BioNTech, Repligen Corp and Ovid Therapeutics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Moderna, Amgen, BioNTech, Repligen Corp and Ovid Therapeutics
Zacks Industry Outlook Highlights: Regeneron, Gilead Sciences, Amgen, Biogen, BioNTech, Repligen and Ovid Therapeutics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Regeneron, Gilead Sciences, Amgen, Biogen, BioNTech, Repligen and Ovid Therapeutics
3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem
by Ekta Bagri
The focus on coronavirus treatments should maintain momentum for the volatile Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BNTX, RGEN and OVID to perform well.
Are Options Traders Betting on a Big Move in Ovid Therapeutics (OVID) Stock?
by Zacks Equity Research
Investors need to pay close attention to Ovid Therapeutics (OVID) stock based on the movements in the options market lately.
Ovid Therapeutics (OVID) Jumps: Stock Rises 12.4%
by Zacks Equity Research
Ovid Therapeutics (OVID) saw a big move last session, as its shares jumped more than 12% on the day, amid huge volumes.
Implied Volatility Surging for Ovid Therapeutics (OVID) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Ovid Therapeutics (OVID) stock based on the movements in the options market lately.
Top Ranked Momentum Stocks to Buy for April 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 22nd
Inovio (INO) Stock Up YTD on Coronavirus Vaccine Efforts
by Zacks Equity Research
Inovio (INO) is developing INO-4800, its DNA vaccine to enter clinical testing soon, against COVID-19. The company's vaccine portfolio holds potential amid competition.
Will Ovid Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Ovid Therapeutics.
Will Ovid Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Ovid Therapeutics.
OVID THERAPEUTC Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
OVID THERAPEUTC Sees Hammer Chart Pattern: Time to Buy?
OVID THERAPEUTC Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
OVID THERAPEUTC has been struggling lately, but the selling pressure may be coming to an end soon.